ALC1 Inhibitors and Synergy with PARPi
AssigneeEisbach Bio GmbH
InventorsWilliam M. Menzer, Gunnar Knobloch, Corinna Lieleg, Adrian Schomburg, Andreas Ladurner, Peter Sennhenn
Life of this patent
Estimating the term…
Loading patent…
AssigneeEisbach Bio GmbH
InventorsWilliam M. Menzer, Gunnar Knobloch, Corinna Lieleg, Adrian Schomburg, Andreas Ladurner, Peter Sennhenn
Estimating the term…
The present invention relates to small molecule compounds that allosterically inhibit ALC1 (CHD1L) and which induce the trapping of PARP1, PARP2 and/or PARP3 on chromatin or at DNA damage sites. Disruption of the chromatin remodeling forces of ALC1 through these agents enables a highly selective therapy for targeting the DNA damage functions of PARP enzymes in several proliferative diseases, notably BRCA-deficient cancers. Via inhibition of the enzymatic activity, the compounds engage the synthetic lethality between BRCA1/2 and ALC1. By trapping PARP enzymes, inhibitors of ALC1 potentiate the cancer cell killing properties of PARP inhibitors, enable therapeutic approaches where ALC1 is amplified as an oncogene, therapeutically make it possible to overcome PARP inhibitor resistance mechanisms and enable an alternative approach to the treatment of germline or acquired BRCA1/BRCA2 deficiency, including tumors defined by “BRCAness” or other changes in DNA repair networks.
1-15. (canceled)
An allosteric inhibitor of Chromodomain-helicase-DNA-binding protein 1-like (ALC1), wherein the allosteric inhibitor has a structure selected of formula (VII):
Dependencies are inferred from the claim text.